Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amin Farah

Cardiovascular Disease Lynwood, CA Medical Doctor

NPI 1902908080 CMS profile 222865

3737 Martin Luther King Jr Blvd, 401, Lynwood, CA 90262

Open in the dashboard

General payments

$5,895

334 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amin Farah of Lynwood, CA is reported in the CMS Open Payments database as having received $5,895 across 334 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $896 48
2024 General $1,110 55
2023 General $974 47
2022 General $744 43
2021 General $1,033 65
2020 General $732 44
2019 General $407 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amin Farah
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Amin Farah were reported at $896. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Amin Farah Cardiovascular Disease median Middle half National median
2019 $407 $450 $127–$1,392 $163
2020 $732 $242 $77–$751 $114
2021 $1,033 $335 $101–$1,037 $132
2022 $744 $395 $121–$1,211 $149
2023 $974 $443 $136–$1,283 $160
2024 $1,110 $450 $136–$1,323 $164
2025 $896 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,218 85 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $852 62 payments
  3. Janssen Pharmaceuticals, Inc $774 46 payments
  4. Merck Sharp & Dohme Corporation $428 20 payments
  5. Amarin Pharma Inc. $380 19 payments
  6. AstraZeneca Pharmaceuticals LP $380 20 payments
  7. E.R. Squibb & Sons, L.L.C. $275 13 payments
  8. Pfizer Inc. $258 13 payments
  9. Scpharmaceuticals Inc. $208 8 payments
  10. Edwards Lifesciences Corporation $141 5 payments
  11. Other $981 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,871 331 payments
  2. Education $24 3 payments
Products named General payments · program years 2019–2025
  1. LifeVest $852 62 payments
  2. XARELTO $774 46 payments
  3. LEQVIO Cardiology/Vascular Diseases $615 40 payments
  4. ENTRESTO Cardiovascular $558 42 payments
  5. VERQUVO $473 22 payments
  6. Vascepa $380 19 payments
  7. ENTRESTO Cardiology/Vascular Diseases $254 14 payments
  8. LEQVIO Cardiovascular $214 14 payments
  9. FUROSCIX $208 8 payments
  10. VYNDAQEL $197 10 payments
  11. Other $2,203 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

5,330

Median for Cardiology: 2,533

Drug cost

$788,797

Median for Cardiology: $485,213

Branded share of claims

17.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 195 $257,064
Xarelto Rivaroxaban Brand 164 $192,493
Entresto Sacubitril/Valsartan Brand 117 $122,364
Jardiance Empagliflozin Brand 49 $56,856
Farxiga Dapagliflozin Propanediol Brand 28 $38,603
Vascepa Icosapent Ethyl Brand 65 $33,271
Icosapent Ethyl Generic 55 $18,699
Ozempic Semaglutide Brand 19 $17,775
Metoprolol Succinate Generic 527 $8,889
Atorvastatin Calcium Generic 656 $6,237

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$217,380

Of which drugs: $966

Medicare patients

543

Average age 75

Services billed

2,934

299 women, 244 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 67%
Heart failure 61%
Ischemic heart disease 54%
Arthritis 51%
Chronic kidney disease 49%
COPD 34%
Atrial fibrillation 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 20 80 $456
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 19 19 $416
Infusion, normal saline solution, 250 cc J7050 Office 22 22 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $131
$131 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $129
$129 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $114
$114 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $94
$94 164 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $54
$54 117 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

334 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record